Skip to main content
. Author manuscript; available in PMC: 2019 Apr 24.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2018 Jul 26;102(5):1569–1576. doi: 10.1016/j.ijrobp.2018.07.192

Figure 4. Blocking CDK4/6 does not alter radiosensitivity of human and mouse cancer cells in vitro.

Figure 4.

(A) Immunoblotting to examine the expression of phosphorylated RB (pRB S780), total Rb and total p53 protein in human HCT116 p53 WT cells and p53 null cells. Cells were treated with palbociclib (PAL) or vehicle for 24 hours before irradiation and were harvested 4 hours after irradiation to analyze protein expression. (B) Clonogenic survival assay of HCT116 p53 WT and p53 null cells after irradiation. Cells were treated with palbociclib (PAL) or vehicle for 24 hours before irradiation and were kept in palbociclib (PAL) for additional 24 hours after irradiation. (C) Clonogenic survival assay was repeated using KrasG12D; p53 null and KrasG12D; Ink4a/Arf null mouse sarcoma cells. No statistically significant difference in clonogenic survival was observed between vehicle and PAL treated cells. (n=3 independent experiments)